BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …

Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …

Abstract Learning Objectives Compare survival outcomes among patients with SCCHN
treated with a platinum/5‐FU regimen with and without cetuximab. Compare adverse event …